Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-058096
Filing Date
2019-11-26
Accepted
2019-11-26 16:10:20
Documents
2
Period of Report
2019-11-22

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1499
2 POA DOCUMENT poa.txt EX-24.3_881055 3708
  Complete submission text file 0001209191-19-058096.txt   6731
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Issuer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Business Address
Meyers James R (Reporting) CIK: 0001387521 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-30171 | Film No.: 191250959